Overview
Allison Martin partners with clients in the patient advocacy and biomedical science space to advance their missions through public policy, advocacy and federal government relations work. Her background in microbiology and immunology and as a senior health care fellow on Capitol Hill enables her to readily identify challenges and opportunities for clients.
Advocacy and Coalition-Building
Allison has extensive experience working with patient advocacy groups, industry and agency leaders on Patient Focused Drug Development activities, such as:
- Building public-private partnerships
- Implementing benefit-risk and burden-of-disease surveys
- Facilitating patient preference work
- Developing community-led drug development guidances
- Developing Patient Focused Drug Development policies
Drawing from her work as a staffer in both the U.S. House and Senate, Allison understands the congressional landscape. She identifies and facilitates introductions and meetings with key government officials and staff. Through her work, she assists coalitions, nonprofit organizations, small and large biopharmaceutical companies, and others to:
- Build relationships with federal agencies and lawmakers
- Develop policies, goals and legislative strategies
- Identify funding opportunities in federal, state, private and venture capital venues
- Monitor and respond to federal laws, regulations and guidance documents
- Plan and execute Congressional advocacy campaigns and communication
Allison is a consulting professional within Faegre Drinker Consulting, and does not act as a lawyer for clients. Learn more about the Faegre Drinker Consulting practice.
Hill Experience
- Sen. Lamar Alexander (R-TN) — Intern
- Rep. Phil Gingrey (R-GA) — Senior Health Care Fellow
Services & Industries
Credentials
Education
Georgetown University
M.S. in Microbiology and Immunology (2012)
Lipscomb University
B.S. in Biology (2009)
International Scholar Laureate Program - Sydney, Australia
Medicine and Public Health Policy (2006)
Insights & Events
Latest
Insights
Other Perspectives
- Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease
Contributor, Parent Project Muscular Dystrophy, June 2014 (Submitted to FDA) - Drug Development for Amyotrophic Lateral Sclerosis, Guidance for Industry
Contributor, ALS Community Developed Guidance, August 2017 (Submitted to FDA) - ALS PREFER, A Platform Initiative for Patient Engagement in Drug Development
Author/Presenter, International Symposium on ALS/MND, December 2017 - Alzheimer’s Disease Patient and Caregiver Engagement Initiative (AD PACE): Determining What Matters Most to Alzheimer’s Patients and Caregivers to Inform the Development of New Therapies, Payment and Coverage Determinations, and Delivery of Care Services
Co-author, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Volume 14, Issue 7, July 2018 - Input from People Living with ALS and Their Caregivers Into Drug Development
Author/Presenter, International Symposium on ALS/MND, December 2018 - Revised Airlie House Consensus Guidelines for Design and Implementation of ALS Clinical Trials
Contributor, Neurology, Volume 92, Number 14, April 2019
Leadership & Community
Civic Activities
- The Ireland Funds Young Leaders — DC Chapter
- LiveBeyond, Thomazeau, Haiti — Volunteer
- Cesar Chavez High School, Washington, D.C. — Tutor
- Lipscomb University, Nashville, Tennessee — Student Senate and Delta Sigma Social Club, Service Coordinator
- Baptist Hospital, Nashville, Tennessee — Volunteer
- Youth Encouragement Services, Nashville, Tennessee — Volunteer
- International Aid, Kiev, Ukraine — Volunteer
- FaegreBD Consulting — Community Service Steering Committee Chair
Honors
- International Scholar Laureate
- Faegre Baker Daniels — Pro Bono Honor Roll, 2018-19